Ann: Update on Phase 2 Trial and IND Progress, page-10

Not too much to worry about here imhop. Results from every single trial Biotron have run have been late in coming. Biotron has always been optimistic with its time frames. This is no different.

Reports come from the people actually doing the trial ie the independent DSMC, so the recent appointment by Biotron is a new one and my guess is aimed at the US ind application.

What is particularly encouraging is the reference to efficacy and possible interaction with other (and presumably the newest) HCV drugs. This may portend trials with these drugs which is pretty much essential if BIT225 is to find its way into common usage.